CureVac (NASDAQ:CVAC) Releases Earnings Results, Beats Estimates By $0.07 EPS

CureVac (NASDAQ:CVAC) issued its quarterly earnings results on Monday. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.07, Zacks reports. CureVac had a net margin of 38.21% and a return on equity of 29.57%.

CureVac Stock Down 0.3%

CVAC stock opened at $5.01 on Monday. The company has a debt-to-equity ratio of 0.05, a current ratio of 6.17 and a quick ratio of 6.16. The company’s 50 day simple moving average is $5.34 and its 200-day simple moving average is $5.16. CureVac has a 12 month low of $2.47 and a 12 month high of $5.72. The firm has a market capitalization of $1.12 billion, a PE ratio of 5.21 and a beta of 2.56.

Hedge Funds Weigh In On CureVac

Several hedge funds have recently bought and sold shares of the stock. Headlands Technologies LLC purchased a new position in CureVac in the 2nd quarter valued at about $35,000. Integrated Wealth Concepts LLC raised its position in shares of CureVac by 25.0% in the first quarter. Integrated Wealth Concepts LLC now owns 15,000 shares of the company’s stock valued at $42,000 after buying an additional 3,000 shares during the last quarter. Squarepoint Ops LLC purchased a new position in shares of CureVac during the third quarter valued at approximately $119,000. Gabelli Funds LLC acquired a new stake in CureVac during the second quarter worth approximately $130,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in CureVac in the 1st quarter worth approximately $142,000. Hedge funds and other institutional investors own 17.26% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “hold (c-)” rating on shares of CureVac in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $6.83.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.